Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM583 Single Ascending Dose Study in Healthy Adult Participants
NCT07823764Phase 1Not yet recruiting
- Sponsor
- Keymed Biosciences
- Start
- Oct 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CM583 in migraine (5 cohorts), sponsored by Keymed Biosciences. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events, Number of Participants With Clinically Significant Physical Examination Abnormalities and 3 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
CM583
03
Conditions
migraine
Beyond the preview
Go deeper on NCT07823764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07823764.